Analysts expect that Clovis Oncology Inc (NASDAQ:CLVS) will report $19.22 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for Clovis Oncology’s earnings. The lowest sales estimate is $18.61 million and the highest is $20.00 million. Clovis Oncology posted sales of $80,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 23,925%. The business is expected to announce its next earnings results on Wednesday, February 28th.

On average, analysts expect that Clovis Oncology will report full year sales of $19.22 million for the current year, with estimates ranging from $55.27 million to $58.47 million. For the next financial year, analysts forecast that the business will report sales of $209.03 million per share, with estimates ranging from $168.20 million to $279.59 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Clovis Oncology.

A number of research firms recently commented on CLVS. Morgan Stanley dropped their price target on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Oppenheimer reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. Stifel Nicolaus reaffirmed a “buy” rating and set a $125.00 price target on shares of Clovis Oncology in a research note on Friday, November 3rd. Finally, BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. Clovis Oncology has a consensus rating of “Hold” and an average target price of $90.43.

In other news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the sale, the director now owns 25,618 shares in the company, valued at approximately $1,537,080. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total transaction of $191,100.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,000 shares of company stock valued at $1,123,425. 12.50% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Clovis Oncology by 18.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,408 shares of the biopharmaceutical company’s stock valued at $2,847,000 after purchasing an additional 4,699 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of Clovis Oncology by 75.0% in the 3rd quarter. Gabelli Funds LLC now owns 15,400 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 6,600 shares in the last quarter. Columbus Circle Investors raised its holdings in shares of Clovis Oncology by 74.4% in the 3rd quarter. Columbus Circle Investors now owns 213,674 shares of the biopharmaceutical company’s stock valued at $17,607,000 after purchasing an additional 91,142 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Clovis Oncology by 1,416.9% in the 3rd quarter. Prudential Financial Inc. now owns 66,560 shares of the biopharmaceutical company’s stock valued at $5,485,000 after purchasing an additional 62,172 shares in the last quarter. Finally, BB&T Securities LLC bought a new stake in shares of Clovis Oncology in the 3rd quarter valued at about $288,000.

Clovis Oncology (NASDAQ CLVS) opened at $56.82 on Monday. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94. The company has a market cap of $2,790.00, a PE ratio of -6.86 and a beta of 1.05.

COPYRIGHT VIOLATION WARNING: “Clovis Oncology Inc (CLVS) Expected to Announce Quarterly Sales of $19.22 Million” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/05/clovis-oncology-inc-clvs-expected-to-announce-quarterly-sales-of-19-22-million.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.